Human respiratory syncytial virus (RSV) is one of the most common viruses to infect children worldwide and now increasingly is recognized as an important pathogen in adults, especially the elderly. Globally each year, there are over 33m episodes of RSV-associated acute lower respiratory infection in children younger than 5 yrs of age resulting at least 3.2m hospital admissions and 59,600 in hospital deaths (2015 estimation, Shi T et al., 2017). In children below 5 yrs, the burden of RSV exceeds that of influenza and other respiratory viral pathogens. There is no specific treatment for RSV infection and for those children who require hospitalization (~1-2% of healthy), supportive therapy is still the mainstay of care.
Palivizumab (anti-RSV monoclonal, Synagis) has been FDA approved since 1998 for the prophylaxis of specific subsets of premature infants.
Newer long-acting monoclonal antibodies such as MEDI8897 (Nirsevimab, MedImmune/AstraZeneca) and MK-1654 (Merck & Co) are currently in clinical development with promising data. A key question is whether these interventions can obviate the need for prophylatic active vaccines.
This MarketVIEW is an Executive Presentation (~80 slides) and MS-Excel forecast model(s) (> 60 worksheets) which investigate the two deployment scenarios and the commercial potential of newer long-acting monoclonal antibodies in all relevant birth types to 2035. 52 countries and sub-regions are included in the model with expected public and private sector use being indicated. A methodology has been created whereby country specific roll-out is forecasted according to specific local factors and RSV transmission patterns which may influence RSV mAb adoption timing.
The report contains a detailed palivizumab (Synagis) case study, review of the R&D competitive environment for new mAbs and expected pricing strategies according to their deployment regime. Discussion/modelling of the interplay between mAbs and RSV vaccines has been added.
This product is ideally suited to organisations wishing to access an up-to-date global quantification of the monoclonal opportunity. It is designed to be complementary to the sister product focused on RSV vaccines (CAT no: VAMV023).
THIS PRODUCT IS A SUMMARY PRESENTATION (~80 slides, .pdf) + 2 scenario-based MS Excel Workbook(s) Photo credit: Hush Naidoo @hush52
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations).
Please review the TERMS and CONDITIONS of purchase.